2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Update on EGFR+ NSCLC: Adjuvant Gefitinib, Adjuvant Osimertinib, Bevacizumab + Erlotinib Final Survival Analysis

101 views
September 22, 2020
Comments 0
Login to view comments. Click here to Login